VIBROSCREEN is a next-generation, handheld Biothesiometer engineered for objective assessment of vibration perception threshold (VPT) in patients at risk of Diabetic Peripheral Neuropathy. The device is optimized for point-of-care diagnostics, enabling rapid, reproducible, and operator-independent screening across clinical, community, and domiciliary settings. Its compact, self-contained architecture, combined with digital integration capabilities, supports large-scale neuropathy screening programs and longitudinal patient monitoring. Technical & Functional Specifications: 1. Handheld, Portable Architecture • Compact, lightweight, and ergonomically engineered for single-handed operation • Suitable for bedside evaluation, outpatient clinics, screening camps, and home healthcare delivery • Battery-powered system ensuring complete operational mobility without dependence on mains supply • Probe geometry optimized for accurate application on plantar surfaces 2. Vibration Stimulus Generation • Employs a precision-controlled electromechanical probe for vibration delivery • Operates at a fixed frequency of 128 Hz, aligned with standard clinical protocols for VPT assessment • Factory-calibrated output ensures high reproducibility and inter-device consistency • Designed to stimulate large myelinated Aβ fibers, facilitating early detection of sensory neuropathy 3. Adjustable Stimulus Amplitude (Voltage-Controlled) • Vibration amplitude is directly proportional to applied voltage, enabling graded stimulus delivery • Continuous and incremental voltage modulation allows accurate determination of perception thresholds • Measurement range typically spans 0–30 V, compliant with established clinical screening thresholds • Supports quantitative sensory testing methodology for neuropathy grading 4. Digital Display & User Interface • Integrated high-contrast OLED display for real-time visualization of VPT values • Displays stimulus intensity (Volts) with high resolution for precise documentation • User-friendly interface minimizes operator training requirements and reduces variability 5. Threshold Measurement & Operating Modes • Manual Mode: o Clinician-controlled application of vibration stimulus at standard anatomical sites o VPT values recorded manually in structured clinical documentation formats • Computer/Mobile-Assisted Mode: o Device interfaces with Windows-based systems or Android platforms o Automated test workflows with guided protocols and standardized site sequencing o Real-time data acquisition, storage, and algorithm-based interpretation o Fully functional in offline environments, ensuring usability in low-resource settings 6. Power Management System • Integrated rechargeable lithium-ion battery with USB Type-C charging interface • Optimized for extended field use with low power consumption architecture • Capable of screening approximately 150–200 patients per full charge cycle • Includes battery status monitoring for uninterrupted clinical workflow 7. Smart Connectivity & Data Integration • Embedded Bluetooth Low Energy (BLE) module for seamless wireless data transfer • Enables integration with mobile and desktop applications for: o Patient data management o Longitudinal tracking and trend analysis o Digital report generation • Supports combined neuropathy screening with: o 10 g Semmes-Weinstein monofilament testing (protective sensation assessment) • Designed for interoperability within a broader diagnostic ecosystem, including: o Ankle-Brachial Index (ABI) systems o Plantar pressure distribution and foot risk assessment platforms Clinical Relevance VIBROSCREEN facilitates early identification of loss of protective sensation (LOPS), a critical risk factor for diabetic foot ulceration and amputation. Its deployment in primary care and screening programs enhances preventive foot care strategies and supports evidence-based clinical decision-making.